Martingale Asset Management L P Akero Therapeutics, Inc. Transaction History

Martingale Asset Management L P

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$41.19 - $52.25 $698,005 - $885,428	16,946 Added 392.81%	21,260 $1.08 Million
Q2 2023 Aug 11, 2023	BUY	$36.89 - $56.88 $159,143 - $245,380	4,314 New	4,314 $201,000
Q2 2022 Aug 11, 2022	SELL	$8.0 - $15.01 $87,160 - $163,533	-10,895 Reduced 41.57%	15,316 $144,000
Q1 2022 May 12, 2022	BUY	$12.97 - $22.26 $27,237 - $46,746	2,100 Added 8.71%	26,211 $371,000
Q4 2021 Feb 11, 2022	BUY	$19.87 - $26.24 $23,844 - $31,487	1,200 Added 5.24%	24,111 $509,000
Q3 2021 Nov 12, 2021	BUY	$18.65 - $25.46 $427,290 - $583,314	22,911 New	22,911 $512,000
Q2 2021 Aug 13, 2021	SELL	$24.81 - $32.35 $176,299 - $229,879	-7,106 Closed	0 $0
Q1 2021 May 13, 2021	BUY	$24.04 - $34.19 $170,828 - $242,954	7,106 New	7,106 $206,000
Q4 2020 Feb 10, 2021	SELL	$25.12 - $29.89 $655,757 - $780,278	-26,105 Closed	0 $0
Q3 2020 Nov 12, 2020	BUY	$30.79 - $39.92 $803,772 - $1.04 Million	26,105 New	26,105 $803,000

209

66.9M

321K

558K

Ticker AKRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,417,600
Market Cap $2.1B
Description
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...

Get notified when there are updates to the investment portfolio of Martingale Asset Management L P, based on Form 13F filings with the SEC.

Stay updated on Martingale Asset Management L P with notifications on news.